This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Acute promyelocytic leukemia (APL)

PHD finger protein 8 (PHF8)

In vitro and mouse studies suggest activating PHF8 could help restore sensitivity of APL to retinoic acid therapy. In retinoic acid-resistant human APL cells, forced expression of the histone demethylase PHF8 restored sensitivity to all-trans retinoic acid (ATRA), whereas expression of a catalytically inactive mutant PHF8 did not. In mice transplanted with retinoid acid-resistant APL cells that expressed wild-type PHF8, compared with mice given resistant APL cells that expressed catalytically inactive PHF8, ATRA decreased leukemia burden. Next steps include identifying compounds that can increase PHF8 activity or reduce the activity of the counteracting histone methyltransferase.

SciBX 6(13); doi:10.1038/scibx.2013.306
Published online April 4, 2013

Unpatented; unavailable for licensing

Arteaga, M.F. et al. Cell; published online March 18, 2013;
doi:10.1016/j.ccr.2013.02.014
Contact: Chi Wai Eric So, King's College London, London, U.K.
e-mail:
eric.so@kcl.ac.uk